Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21032122 | 0.81 | NOTUM (0.45) | NOTUMMALT1CYP19A1KMT2A | |
| SCHEMBL19814315 | 0.79 | MALT1 (0.50) | NOTUMMALT1HCRTR1HCRTR2KMT2A | |
| SCHEMBL22642750 | 0.78 | NOTUM (0.50) | NOTUMHCRTR1HCRTR2EGLN2 | |
| SCHEMBL21030743 | 0.74 | NOTUM (0.40) | NOTUMHCRTR1HCRTR2EGLN2 | |
| SCHEMBL1671789 | 0.73 | HCRTR1 (0.49) | NOTUMHCRTR1HCRTR2EGLN2ALDH1A1 | |
| SCHEMBL28050840 | 0.70 | NOTUM (0.46) | NOTUMHCRTR1HCRTR2CYP19A1EGLN2 | |
| SCHEMBL1473291 | 0.69 | NOTUM (0.37) | NOTUMMALT1CYP19A1 | |
| SCHEMBL14923452 | 0.68 | NOTUM (0.40) | NOTUMHCRTR1HCRTR2CYP19A1EGLN2 | |
| SCHEMBL13629601 | 0.67 | NOTUM (0.58) | NOTUMHCRTR1HCRTR2CYP19A1KMT2A | |
| SCHEMBL6127790 | 0.67 | PSEN1 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190275012-A9 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | LUPIN LIMITED (IN) | 2019-09-12 | — | — | US | disclosed |
| US-20190160045-A1 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | LUPIN LTD (IN) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275012-A9 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | MALT1, PTP4A1, PTPRO | NOTUM 2566/4885MALT1 1/4885HCRTR1 4327/4885 |
| US-20190160045-A1 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | MALT1, PTP4A1, PTPRO | NOTUM 2566/4885MALT1 1/4885HCRTR1 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.